The place of sulfonylureas in the therapy for type 2 diabetes mellitus

Prato, Stefano Del; Pulizzi, Nicolò

doi:10.1016/j.metabol.2006.02.003

Cited by 131 publications

(83 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intensive treatment of diabetes with gliclazide MR in the study ADVANCE resulted in significant reduction of microvascular complications (18). Gliclazide MR causes less hypoglycemia than chlorpropamide and glibenclamide (16,19). In the GUIDE study (20), the rate of hypoglycemia was significantly lower with gliclazide MR as compared to glimepiride.…”

Section: Introductionmentioning

confidence: 91%

Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes

Vilar

Canadas

Arruda

et al. 2010

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Objective: To compare the efficacy and tolerability of metformin, rosiglitazone and gliclazide MR as monotherapy and in combination in the treatment of type 2 diabetes. Subjects and methods: 250 patients treated with oral antidiabetic agents for at least 24 weeks in monotherapy or in combination therapy were included in this retrospective study. Results: As monotherapy the reduction of fasting plasma glucose (FPG), postprandial glycemia (PPG) and HbA1c was similar with the three drugs after 24 weeks. Among patients on combination therapy, the reduction in HbA1c, FPG and PPG was significantly lower with rosiglitazone plus metformin, as compared to metformin plus gliclazide MR or gliclazide MR plus rosiglitazone. Patients treated with rosiglitazone achieved less favorable changes in lipid profile. Conclusion: In monotherapy all drugs were equally effective in improving glycemic control, whereas the combination of metformin plus gliclazide MR provided the best results concerning the improvement of both, glycemic control and lipid profile. Arq Bras Endocrinol Metab. 2010;54(3):311-8 Keywords Metformin; glicazide MR; rosiglitazone RESUMO Objetivo: Comparar a eficácia e a tolerabilidade da metformina, rosiglitazona e gliclazida MR em monoterapia ou em combinação no tratamento do diabetes tipo 2. Sujeitos e métodos: 250 pacientes tratados com antidiabéticos orais por pelo menos 24 semanas, em monoterapia ou em terapia combinada, foram incluídos neste estudo retrospectivo. Resultados: Como monoterapia, a redução da glicemia de jejum (GJ), glicemia pós-prandial (GPP) e HbA1c foi similar com as três drogas, após 24 semanas. Entre os pacientes em terapia combinada, a redução da HbA1c, GJ e GPP foi significativamente menor com rosiglitazona e metformina, em comparação com metformina e gliclazida MR ou gliclazida MR mais rosiglitazona. Os pacientes tratados com rosiglitazona obtiveram mudanças menos favoráveis no perfil lipídico. Conclusão: Em monoterapia todos os medicamentos foram igualmente eficazes na melhora do controle glicêmico, enquanto a combinação de metformina e gliclazida MR proporcionou os melhores resultados relativos à melhoria de ambos, controle glicêmico e perfil lipídico. Arq Bras Endocrinol Metab. 2010;54(3):311-8

show abstract

Section: Introductionmentioning

confidence: 91%

Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes

Vilar

Canadas

Arruda

et al. 2010

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…Also, sulphonylureas can be used to trigger insulin release from β-cells through opening of calcium channels (6). However, sulphonylureas have been prescribed with many restrictions due to side-effects, leading to hypoglycemia via the gradual β-cell destruction and impaired endothelial cell function (7). Most of the current drugs used for type 2 diabetes patients are not free from side effects and do not restore normal glucose homeostasis (8).…”

Section: Introductionmentioning

confidence: 99%

Polysaccharide isolated from Triticum aestivum stimulates insulin release from pancreatic cells via the ATP-sensitive K+ channel

et al. 2012

View full text Add to dashboard Cite

Abstract. Traditional natural plants have been used throughout the world for their antidiabetic effects. The aim of the present study was to investigate the stimulating activity of a polysaccharide extract derived from T. aestivum sprout (TASP) on insulin secretion in vitro using the RIN-5F pancreatic β-cell line and rat pancreatic islets. In these experiments, TASP (0.1 to 2 mg/ml) augmented glucose-stimulated insulin secretion in a dose-dependent manner in the presence of a stimulatory glucose concentration (16.7 mM), but not of a basal concentration (1.1 mM). Although TASP failed to enhance the high K + -induced insulin secretion, the insulinotropic effect of TASP was significantly inhibited by diazoxide, an opener of ATP-sensitive K + channel blocking insulin release. TASP potentiated the insulin secretion induced by other secretagogues, such as IBMX and tolbutamide. Moreover, glucose-derived blood insulin levels were significantly elevated by oral administration of TASP to mice, similarly to antidiabetic drugs. We also demonstrated that TASP significantly increased glucose-induced 45 Ca2+ uptake and proinsulin mRNA expression in rat islets. Overall, our results suggest that TASP has a stimulating effect on insulin secretion and production in pancreatic β-cells via K + channel closure and calcium influx. These results suggest that TASP may be useful as a candidate for the therapy of diabetes mellitus.

show abstract

“…A series of publications over many years have told us that SUs increase the risk of adverse cardiovascular outcomes in diabetes patients (usually relative to metformin in observational studies), 1 analyses from ACCORD and other mega trials have heightened concern over severe hypoglycaemia as a risk factor for premature mortality 2 and it is not uncommon to hear that SUs induce β-cell exhaustion. 3 The place of metformin (with lifestyle intervention) looks secure at the head of the management algorithm for type 2 diabetes, for the time being at least. 4,5 But most type 2 diabetes patients will need the addition of a second pharmacological agent to their regimen at some point, as their β-cell function continues to wane.…”

Section: Setting the Scenementioning

confidence: 99%

This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes

2016

View full text Add to dashboard Cite

The place of sulfonylureas in the therapy for type 2 diabetes mellitus

Cited by 131 publications

References 54 publications

Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes

Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes

Polysaccharide isolated from Triticum aestivum stimulates insulin release from pancreatic cells via the ATP-sensitive K+ channel

This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes

Contact Info

Product

Resources

About